Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma

BACKGROUND: Even in the era of novel immunotherapies for multiple myeloma (MM), treatment of late‐stage relapsed/refractory (RR) patients remains challenging. The aim of our study was to analyze the efficacy and safety of the five‐drug combination pomalidomide, bortezomib, doxorubicin, dexamethasone...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Xiang, Steinhardt, Maximilian J., Grathwohl, Denise, Meckel, Katharina, Nickel, Katharina, Leicht, Hans‐Benno, Krummenast, Franziska, Einsele, Hermann, Rasche, Leo, Kortüm, Klaus M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7433809/
https://www.ncbi.nlm.nih.gov/pubmed/32608149
http://dx.doi.org/10.1002/cam4.3209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7433809/
https://www.ncbi.nlm.nih.gov/pubmed/32608149
http://dx.doi.org/10.1002/cam4.3209

Ejemplares similares